Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.62 |
| ▸ | DPP4 | P27487 | 6/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5746200 | 1.00 | HDAC8 (0.62) | HDAC8DPP4SLC7A5OPRD1SMYD3 | |
| SCHEMBL3140448 | 0.87 | DPP4 (0.60) | HDAC8DPP4HRH2HRH1 | |
| SCHEMBL6164614 | 0.87 | HDAC8 (0.64) | HDAC8DPP4SLC7A5OPRD1 | |
| SCHEMBL7567649 | 0.87 | HDAC8 (0.64) | HDAC8DPP4SLC7A5OPRD1 | |
| SCHEMBL7566120 | 0.87 | HDAC8 (0.64) | HDAC8DPP4SLC7A5OPRD1 | |
| SCHEMBL14390395 | 0.86 | HDAC8 (0.67) | HDAC8DPP4SLC7A5OPRD1SMYD3 | |
| SCHEMBL27388252 | 0.84 | HDAC8 (0.63) | HDAC8DPP4SLC7A5OPRD1SMYD3 | |
| Trifluoroacetic Acid SCHEMBL9055785 | 0.81 | HDAC8 (0.57) | HDAC8DPP4SLC7A5OPRD1 | |
| Hydrochloric Acid SCHEMBL6165132 | 0.80 | HDAC8 (0.61) | HDAC8DPP4SLC7A5OPRD1SMYD3 | |
| Hydrochloric Acid SCHEMBL6165142 | 0.80 | HDAC8 (0.61) | HDAC8DPP4SLC7A5OPRD1SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487449-A4 | TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS | KING PHARMACEUTICALS RES & DEV (US) | 2006-08-23 | — | — | EP | claimed |
| US-7094895-B2 | Tyrosyl derivatives and their use as P2X7 receptor modulators | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2006-08-22 | — | — | US | claimed |
| EP-1487449-A1 | TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS | King Pharmaceuticals Research and Development Inc. (US) | 2004-12-22 | — | — | EP | claimed |
| US-20030181452-A1 | Tyrosyl derivatives and their use as P2X7 receptor modulators | CREDIT SUISSE AG | 2003-09-25 | — | — | US | claimed |
| WO-2003059353-A1 | TYROSYL DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2003-07-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181452-A1 | Tyrosyl derivatives and their use as P2X7 receptor modulators | P2RX7, P2RX3, P2RX5 | HDAC8 3270/4885DPP4 556/4885SLC7A5 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.